Our systematic review and meta-analysis will establish summary estimates on CHIP’s performance as a prognostic tool, thereby informing the net clinical benefit associated with CHIP screening in the general population and individuals with established cardiovascular disease. The gene discussed is STUB1; the disease is cardiovascular disorder.